Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Drug Name | ZN-A-1041 |
Trade Name | |
Synonyms | ZN-A 1041|ZN-A1041 |
Drug Descriptions |
ZN-A-1041 inhibits ERBB2 (HER2)-mediated downstream signaling, potentially resulting in tumor cell death (NCI Drug Dictionary). |
DrugClasses | HER2 Inhibitor 38 |
CAS Registry Number | NA |
NCIT ID | C178299 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Ado-trastuzumab emtansine + ZN-A-1041 | Ado-trastuzumab emtansine ZN-A-1041 | 0 | 1 |
Pertuzumab + Trastuzumab + ZN-A-1041 | Pertuzumab Trastuzumab ZN-A-1041 | 0 | 1 |
Pertuzumab/trastuzumab/hyaluronidase-zzxf + ZN-A-1041 | Pertuzumab/trastuzumab/hyaluronidase-zzxf ZN-A-1041 | 0 | 1 |
Trastuzumab deruxtecan + ZN-A-1041 | Trastuzumab deruxtecan ZN-A-1041 | 0 | 1 |
ZN-A-1041 | ZN-A-1041 | 0 | 1 |